Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 8/20 | 1.00 |
| ▸ | GRM2 | Q14416 | 4/20 | 1.00 |
| ▸ | GRM3 | Q14832 | 4/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 4/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 4/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 3/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 1.00 |
| ▸ | GRM8 | O00222 | 2/20 | 1.00 |
| ▸ | GRM6 | O15303 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | GRM5 | P41594 | 1/20 | 1.00 |
| ▸ | MTOR | P42345 | 1/20 | 1.00 |
| ▸ | GRM1 | Q13255 | 1/20 | 1.00 |
| ▸ | PLCB1 | Q9NQ66 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.68 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4835874 | 1.00 | GRM4 (1.00) | GRM4GRM2GRM3CYP1A2CYP2C19 | |
| SCHEMBL3125919 | 1.00 | GRM4 (1.00) | GRM4GRM2GRM3CYP1A2CYP2C19 | |
| SCHEMBL935371 | 1.00 | GRM4 (1.00) | GRM4GRM2GRM3CYP1A2CYP2C19 | |
| SCHEMBL481144 | 1.00 | GRM4 (1.00) | GRM4GRM2GRM3CYP1A2CYP2C19 | |
| SCHEMBL719389 | 1.00 | GRM4 (1.00) | GRM4GRM2GRM3CYP1A2CYP2C19 | |
| SCHEMBL2157698 | 1.00 | GRM4 (1.00) | GRM4GRM2GRM3CYP1A2CYP2C19 | |
| SCHEMBL179741 | 1.00 | GRM4 (1.00) | GRM4GRM2GRM3CYP1A2CYP2C19 | |
| SCHEMBL2916853 | 0.88 | GRM4 (0.78) | GRM4GRM2GRM3CYP1A2CYP2C19 | |
| SCHEMBL4835681 | 0.88 | GRM4 (0.78) | GRM4GRM2GRM3CYP1A2CYP2C19 | |
| SCHEMBL7271016 | 0.88 | GRM4 (0.78) | GRM4GRM2GRM3CYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 421 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260119915-A1 | SENTIX-IED - Decision State Intelligence System | JUNIOR JOSE REGINALDO VALENTE (BR) | 2026-04-30 | — | — | US | claimed |
| EP-4677075-A2 | TARGETING CELLS IN STRESSED GROWING CONDITIONS | SNIPR Biome ApS (DK) | 2026-01-14 | — | — | EP | claimed |
| US-20250032530-A1 | USE OF AURANOFIN AS AN INHIBITOR OF ATYPICAL PROTEIN KINASE C FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | UNIVERSITY OF SOUTH FLORIDA | 2025-01-30 | — | — | US | claimed |
| WO-2024184403-A2 | TARGETING CELLS IN STRESSED GROWING CONDITIONS | SNIPR BIOME APS (DK) | 2024-09-12 | — | — | WO | claimed |
| US-20240075047-A1 | aPKC INHIBITORS AND METHODS OF TREATING A NEURODEGENERATIVE DISEASE OR DISORDER | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS | 2024-03-07 | — | — | US | claimed |
| US-11915702-B1 | Automated systems and methods that generate affect-annotated timelines | Affective Software, Inc. (US) | 2024-02-27 | — | — | US | claimed |
| WO-2023076936-A1 | USE OF AURANOFIN AS AN INHIBITOR OF ATYPICAL PROTEIN KINASE C FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | FARESE ROBERT VITO (US) | 2023-05-04 | — | — | WO | claimed |
| US-20220241226-A1 | Method of Treating Colorectal Cancers Using a PKC Inhibitor | UNIV SOUTH FLORIDA (US) | 2022-08-04 | — | — | US | claimed |
| US-11337944-B2 | Method of treating colorectal cancers using a PKC inhibitor | UNIVERSITY OF SOUTH FLORIDA (US) | 2022-05-24 | — | — | US | claimed |
| EP-1038023-A1 | AGONISTS OF METABOTROPIC GLUTAMATE RECEPTORS AND USES THEREOF | THE UAB RESEARCH FOUNDATION (US) | 2000-09-27 | — | — | EP | claimed |
| US-6013672-A | ADMINISTERING TO AN INDIVIDUAL SUFFERING FROM HEAD, SPINAL CORD TRAUMA, STROKE AND EPILEPSY A THERAPEUTICALLY EFFECTIVE DOSE OF A METABOTROPIC GLUTAMATE RECEPTOR AGONIST | UAB RESEARCH FOUNDATION (US) | 2000-01-11 | — | — | US | claimed |
| US-6001581-A | Cation-based bioassay using human metabotropic glutamate receptors | SIBIA NEUROSCIENCES, INC. (US) | 1999-12-14 | — | — | US | claimed |
| WO-1999031268-A1 | AGONISTS OF METABOTROPIC GLUTAMATE RECEPTORS AND USES THEREOF | UAB RESEARCH FOUNDATION (US) | 1999-06-24 | — | — | WO | claimed |
| US-5635608-A | CONTAINS PHOTOREMOVABLE ALPHA-CARBOXY-SUBSTITUTED ORTHO-NITROBENZYL GROUP THAT CHANGES THE FLUORESCENCE AND BIOLOGICAL PROPERTIES OF THE COMPOUND | MOLECULAR PROBES, INC. (US) | 1997-06-03 | — | — | US | claimed |
| EP-4677075-A2 | TARGETING CELLS IN STRESSED GROWING CONDITIONS | SNIPR Biome ApS (DK) | 2026-01-14 | — | — | EP | disclosed |
| US-20260002165-A1 | TARGETING CELLS IN STRESSED GROWING CONDITIONS | SNIPR BIOME APS (DK) | 2026-01-01 | — | — | US | disclosed |
| EP-4627103-A1 | IMPEDIMETRIC DETECTION USING PEPTIDE AND PEPTIDE MIXTURES | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (IL) | 2025-10-08 | — | — | EP | disclosed |
| EP-0497884-A1 | GLUTAMATE RECEPTOR COMPOSITIONS AND METHODS | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 1992-08-12 | — | — | EP | disclosed |
| WO-1992010583-A1 | G PROTEIN-COUPLED GLUTAMATE RECEPTORS | ZYMOGENETICS, INC. (US) | 1992-06-25 | — | — | WO | disclosed |
| WO-1991006648-A1 | GLUTAMATE RECEPTOR COMPOSITIONS AND METHODS | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 1991-05-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260002165-A1 | TARGETING CELLS IN STRESSED GROWING CONDITIONS | ATF4, BACH1, ATF1 | GRM4 4877/4885GRM2 4855/4885GRM3 4868/4885 |
| US-20260119915-A1 | SENTIX-IED - Decision State Intelligence System | IKBKG, TSNAX, FHIT | GRM4 727/4885GRM2 2398/4885GRM3 3084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.